MedTrace Logo

Almonertinib Plus Metronomic Oral Vinorelbine

NCT05663177 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-12-23

No results posted yet for this study

Summary

To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.

Conditions

  • EGFR
  • NSCLC
  • Third-generation TKI

Interventions

DRUG

Almonertinib and metronomic oral vinorelbine

Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2023-12-20
Completion
2024-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05663177 on ClinicalTrials.gov